KRP-AM1977Y Phase II Clinical Study
Phase 2
Completed
- Conditions
- Mild to severe community acquired pneumonia (including Mycoplasma pneumonia, Chlamydia Pneumonia, or Legionella pneumonia)
- Registration Number
- JPRN-jRCT2080222567
- Lead Sponsor
- Kyorin Pharmaceutical Co.,LTD
- Brief Summary
The cure rates at the test-of-cure were more than 90% in both the KRP-AM1977Y 75 mg and the 150 mg groups. A high clinical efficacy was observed in both groups.In the safety assessment, no major problem was observed in both administration groups. No clinically significant finding was reported in both treatment groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
Community acquired pneumonia with clear infectious symptoms
Exclusion Criteria
- Pneumonia patient except the community-acquired pneumonia
- Patient with serious functional disorder that would unsuitable for the study
- Patient showing the tendency to improve pneumonia symptoms by other agents, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method